GROWING IMPACT OF BLOOD CANCER ON WOMEN Increasing incidence rates, mortality and disease burden forecast over coming decade
With
Chris Tanti, CEO
Leukaemia Foundation
SEGMENT
Filmed in Melbourne | December 2025
According to the Leukaemia Foundation, blood cancer is one of the most urgent and under-recognised women’s health issues in Australia, with three times more Australian women diagnosed with blood cancer than ovarian and cervical cancer combined (Source: AIHW, Cancer Data in Australia, 2024).
Blood cancer has also emerged as the second most common cancer diagnosed in Australian women overall – behind only breast cancer – and the leading cancer amongst girls and women under the age of 30 (Source: AIHW, Cancer Data in Australia, 2024).
Women face longer, more intensive treatment regimens than many other cancers, often requiring lengthy hospital stays or relocation to a capital city to access specialist care. Treatments such as chemotherapy and radiotherapy can also cause irreversible infertility.
The financial and emotional burden of blood cancer on women is equally severe:
- Women with blood cancer are more likely to be out of work than those with other leading cancers.
- 42% of patients are forced to take more than three months off work, 30% leave their jobs entirely, and half have not been able to return to work.
- Patients face average out-of-pocket costs of $5,000–$11,000, compared to $2,500 for other cancers
- 70% of people with blood cancer experience emotional challenges after diagnosis.
Women also make up 72% of Australia’s primary carers, yet with a debilitating diagnosis like blood cancer, their ability to care for others is significantly diminished, impacting families and communities nationwide.
Australian Health Journal spoke with Leukaemia Foundation CEO, Chris Tanti about the toll, blood cancer takes on women’s lives beyond the physical fight for survival, as well as the alarming forecasts on the expected increase over the next decade. Mr Tanti talks about the need to increased levels of medical research into blood cancer to balance against other leading cancers, to investigate prevention, early detection, and diagnosis.
About Leukaemia Foundation
For the past 50 years, the Leukaemia Foundation has been caring for and supporting Australians affected by blood cancer by providing accommodation while they are undergoing treatment, assistance with transport to appointments, education and information about their blood cancer, as well as other practical, financial, emotional and mental health support.
Source: Adapted from Leukaemia Foundation media release September 2025
-
In development, age specific clinical practice guidelines for early onset bowel cancer
The National Health and Medical Research Council (NHMRC) has agreed to consider for approval the Clinical Practice Guidelines for the Early Diagnosis and Management of Early-Onset Colorectal Cancer (EOCRC), to be developed by Bowel Cancer Australia in collaboration with the Australian Living Evidence Collaboration (ALEC), and funded by Bowel Cancer Australia. ALEC is led by Cochrane Australia and based in the School of Public Health and Preventive Medicine at Monash University.
-
Clinical trial site in primary care setting open for novel therapies in psychiatry
Over the past decade, Paratus has been involved in over 200 clinical trials across 4 clinical site locations. Now a fifth site, the newly opened Melbourne site will cater to both primary care and psychiatry, specifically designed for psychedelic studies.
The new Melbourne site will be a focused on primary care studies specifically expanding access to psychiatric research, a growing area of unmet need. Australian Health Journal met with 3 recent hires brought in to support clinical trials across the organisation and in psychiatry in Melbourne.
-
Redefining diversity in clinical trials
Ensuring inclusion, diversity, equity and patient input in the development of novel drugs and medical devices has become well accepted in health care. However appropriate implementation of these elements has been a challenge for many. Only by implementing these conscious inputs can patient outcomes be improved and health disparities in marginalised groups be addressed.
Australian Health Journal spoke to Gillian Mason, Consumer and Community Involvement Lead at Hunter Medical Research Institute in Newcastle, NSW on this topic discussed at the recent ARCS Conference in Sydney.
